Sacubitril/valsartan for chronic heart failure: its future potential

Abstract

Sacubitril/valsartan (Entresto), a combined neprilysin inhibitor/angiotensin II‐receptor antagonist for the treatment of chronic heart failure with reduced ejection fraction, was launched in the UK in January. The phase 3 clinical trial PARADIGM‐HF established its efficacy in chronic heart failure but what is its future place in therapy, according to the latest guidelines and research?